13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q1 2025 · Filed May 15, 2025 · Accession 0000950123-25-005509
Total Value
$169.5M
Positions
13
Other Managers
0
Confidential Omitted
No
Holdings (13)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Kestra Med Technologies Ltd. | BEKE | 1,795,893 | $44.8M | 26.41% |
| 2 | Bicara Therapeutics Inc. | BCAX | 2,204,650 | $28.7M | 16.95% |
| 3 | Beta Bionics Inc. | BBNX | 1,988,287 | $24.3M | 14.36% |
| 4 | Nuvation Bio | NUVB | 13,072,340 | $23.0M | 13.58% |
| 5 | Replimune Group | REPL | 1,975,203 | $19.3M | 11.36% |
| 6 | Upstream Bio Inc. | UPB | 2,036,293 | $12.5M | 7.35% |
| 7 | Lexeo Therapeutics | LXEO | 1,184,636 | $4.1M | 2.43% |
| 8 | Alumis Inc. | ALMS | 653,223 | $4.0M | 2.37% |
| 9 | Ikena Oncology | 45175G108 | 2,249,123 | $2.9M | 1.70% |
| 10 | enGene Holdings Inc. | ENGNW | 526,357 | $2.4M | 1.39% |
| 11 | Immunic Inc. | IMUX | 1,788,160 | $1.9M | 1.15% |
| 12 | Sana Biotechnology, Inc. | SANA | 843,750 | $1.4M | 0.84% |
| 13 | enGene Holdings Inc. | ENGNW | 321,502 | $192,901 | 0.11% |